CN Patent

CN102652022A — 治疗干眼综合征的药物组合物

Assigned to Novaliq GmbH · Expires 2012-08-29 · 14y expired

What this patent protects

本发明提供了治疗干燥性角膜结膜炎的新的药物组合物，该组合物包括包含一种或多种半氟化烷烃的液体介质。该组合物包括选自由大环内脂类免疫抑制剂组成的组的活性成分。其可向眼睛中局部施用。本发明还提供了包含这样的组合物的试剂盒。

USPTO Abstract

本发明提供了治疗干燥性角膜结膜炎的新的药物组合物，该组合物包括包含一种或多种半氟化烷烃的液体介质。该组合物包括选自由大环内脂类免疫抑制剂组成的组的活性成分。其可向眼睛中局部施用。本发明还提供了包含这样的组合物的试剂盒。

Drugs covered by this patent

Patent Metadata

Patent number
CN102652022A
Jurisdiction
CN
Classification
—
Expires
2012-08-29
Drug substance claim
No
Drug product claim
No
Assignee
Novaliq GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.